Senior Appointments at Investment Adviser

RNS Number : 4514Z
Life Science REIT PLC
25 January 2022
 

25 January 2022

LEI: 213800RG7JNX7K8F7525

 

Life Science REIT plc

("Life Science REIT" or the "Company")

 

Investment Adviser Makes Key Senior Appointments

Life Science REIT (AIM: LABS) the real estate investment trust focused on UK life science properties, is pleased to announce three senior appointments at the Company's Investment Adviser, Ironstone Asset Management Ltd ("Ironstone").

Ian Harris joins as Director of Asset Management. Ian is a qualified chartered surveyor with over 30 years' experience in the UK real estate market. His career includes senior roles at CBRE Global Investors, Imry Holdings and Frame Investments Ltd. Most recently he co-founded Westmount Real Estate Ltd, a boutique investment advisory and asset management business acting for a wide range of domestic and international investors.

Matthew Barker has been appointed to the role of Senior Asset Manager. Matthew is an experienced asset manager and chartered surveyor with over 10 years of experience in the UK real estate market, including the role of asset manager at the listed REIT Picton Property Income Ltd. He joins from Mayfair Capital where he held the same role.

In addition, David Lewis is now Director of Operations and Finance consolidating the two roles and replacing Andrew Pinto, who has now left Ironstone.  David has over 30 years' commercial and financial experience, most recently as Head of Fund Finance at Round Hill Capital, a real estate private equity firm. He has held a number of senior executive positions, including European CFO of investment manager Babcock & Brown, in addition to roles at Balfour Beatty Investments, Campus Living Villages and Lend Lease Infrastructure.

Simon Farnsworth, Managing Director of Ironstone Asset Management Ltd, the Company's Investment Adviser, said:

"We are delighted to announce today's appointments at the Ironstone team. They provide significant additional expertise to the team's extensive investment capabilities and experience and I look forward to working with them.

"In a little over two months since our IPO, we are pleased to have deployed over half of the IPO proceeds in five, high quality, immediately income producing life science transactions across the Golden Triangle of London, Oxford and Cambridge. We look forward to updating shareholders on the progression of our active pipeline of highly attractive opportunities in due course."

 

FOR FURTHER INFORMATION, PLEASE CONTACT:

Ironstone Asset Management - Investment Adviser

 

Simon Farnsworth

via Buchanan below

 

 

Panmure Gordon - Nominated Adviser and Joint Corporate Broker

+44 20 7886 2500

Atholl Tweedie / Sapna Shah / Philip Shields / Chloe Ponsonby

 

 

 

Jefferies International Limited - Joint Corporate Broker

+44 20 7029 8000

Tom Yeadon / Andrew Morris / Oliver Nott 

 

 

 

Buchanan - Financial PR

+44 20 7466 5000

Mark Court / Henry Wilson / Verity Parker

LifeSciencereit@buchanan.uk.com 

 

 

Notes to editors

Life Science REIT plc is a property business focused solely on the UK's growing life science sector, specifically targeting opportunities in the "Golden Triangle" research and development hubs of Oxford, Cambridge and London St Pancras. The Company's intention is to become the property provider of choice for life science companies in the UK, whilst enabling shareholders to gain exposure to a specific growth sector. 

The objective of the Company's investment policy is focused on capital growth, whilst also providing a growing level of income, by investing primarily in a diversified portfolio of properties that are leased, or intended to be leased, to tenants operating in the life science sector in the UK. 

Life Science REIT joined the AIM market of the London Stock Exchange on 19 November 2021, having raised £350 million in its IPO. Its shares trade under the ticker LABS.

Further information is available at https://lifesciencereit.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APPEANFLAFNAEFA
UK 100

Latest directors dealings